Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt | GenomeWeb

This article has been updated with additional details about the strategic alliance.

Alnylam Pharmaceuticals this week announced that it has signed a deal to develop and commercialize RNAi-based treatments for TTR-mediated amyloidosis with Genzyme, giving the Sanofi subsidiary product rights in Asia.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.